Cagrilintide vs Semaglutide: Comparing the Amylin and GLP-1 Research Peptides
Cagrilintide and semaglutide come from two different hormone families, yet they are frequently studied together. One is an amylin analog; the other is a GLP-1 agonist. Their mechanisms are complementary rather than overlapping, which is precisely why researchers have paired them. This article contrasts cagrilintide, a long-acting amylin analog, with semaglutide, a GLP-1 receptor agonist, and explains why the two are of interest in combination.
Two hormone families, two mechanisms
Semaglutide is a 31-amino-acid analog of GLP-1. It resists dipeptidyl peptidase-4 (DPP-4) degradation through an aminoisobutyric acid substitution at position 8, binds albumin through a C18 fatty diacid chain, and acts on the GLP-1 receptor to drive glucose-dependent insulin secretion, glucagon suppression in the fed state, slowed gastric emptying, and central appetite signaling. It is one of the most thoroughly characterized peptides in metabolic research.
Cagrilintide is a long-acting analog of amylin, a hormone co-secreted with insulin from pancreatic beta cells. Native amylin is short-lived and prone to aggregation, so cagrilintide is engineered for stability and extended action and behaves as a co-agonist at the amylin receptor and the related calcitonin receptor. Amylin signaling contributes to satiety, slows gastric emptying, and modulates glucagon, but it does so through a receptor system entirely separate from the incretin axis that semaglutide targets.
| Attribute | Cagrilintide | Semaglutide |
|---|---|---|
| Hormone family | Amylin | Incretin (GLP-1) |
| Class | Long-acting amylin analog | GLP-1 receptor agonist |
| Receptor targets | Amylin and calcitonin receptors | GLP-1 receptor |
| Peptide basis | Stabilized amylin analog | 31-amino-acid GLP-1 analog |
| Half-life design | Long-acting, several days | About one week |
| Research maturity | Emerging, often studied in combination | Extensively characterized |
Why the mechanisms are complementary
The reason cagrilintide and semaglutide are so often paired in research is that they reach overlapping outcomes - reduced food intake and improved metabolic signaling in model systems - through distinct receptor pathways. Amylin and GLP-1 act on separate receptor families, so activating both engages two independent routes to satiety rather than pushing harder on a single one. In preclinical and translational work, this kind of parallel signaling has been of interest for whether two complementary mechanisms produce effects that a single pathway does not, and whether engaging separate receptors changes how the combined signal behaves compared with either compound alone.
There is also a practical design logic. A GLP-1 agonist and an amylin analog each slow gastric emptying and each influence central appetite circuits, but they do so from different molecular starting points. Studying them together lets investigators ask which effects are additive across the two axes and which are specific to one hormone family. This is the same comparative reasoning used when incretin mono-agonists are set against dual or triple agonists, only here the second mechanism comes from the amylin system rather than from another incretin receptor.
How this shapes research use
Semaglutide brings a deep, mature characterization record and a single well-mapped receptor, which makes it a reliable reference arm in any comparison. Cagrilintide is newer and is most often examined in combination studies, where its amylin-and-calcitonin receptor activity is layered alongside GLP-1 signaling. Used together, the two peptides form a natural pairing for probing complementary metabolic pathways, and understanding the GLP-1 side first, as covered in the semaglutide research overview, makes the contrast easier to interpret. The broader metabolic research overview places both compounds within the wider landscape.
Handling and concentration notes
Both peptides are supplied as lyophilized powder and reconstituted with bacteriostatic water. Concentration is worked out the same way for each: divide the vial content in milligrams by the diluent volume in milliliters, then convert to micrograms per milliliter for fine measurement. A 5 mg vial reconstituted with 1 mL yields 5 mg per mL, which is 5000 mcg per mL. The interactive reconstitution calculator walks through these conversions and shows how the figures map onto a graduated syringe as a laboratory measurement task, and independent purity data on the analysis page confirm identity and content. Lyophilized material is stored cold before reconstitution; solutions are kept refrigerated and protected from light, with working stability determined by the specific preparation.
Research use only. This article is educational and is not medical, legal, or financial advice. The compounds discussed are not approved for human or veterinary use, consumption, or therapeutic application.